Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
OR5AN1 Biologics Sequence Review Report 2026: Olfactory receptor 5AN1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR5AN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OR51E2 Biologics Sequence Review Report 2026: Olfactory receptor 51E2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR51E2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OR1A1 Biologics Sequence Review Report 2026: Olfactory receptor 1A1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR1A1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OR10J5 Biologics Sequence Review Report 2026: Olfactory receptor 10J5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR10J5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OR10G3 Biologics Sequence Review Report 2026: Olfactory receptor 10G3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR10G3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OR10C1 Biologics Sequence Review Report 2026: Olfactory receptor 10C1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR10C1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OPCML Biologics Sequence Review Report 2026: Opioid-binding protein/cell adhesion molecule Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OPCML sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OLR1 Biologics Sequence Review Report 2026: Oxidized low-density lipoprotein receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OLR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NSMF Biologics Sequence Review Report 2026: NMDA receptor synaptonuclear signaling and neuronal migration factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NSMF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NRROS Biologics Sequence Review Report 2026: Transforming growth factor beta activator LRRC33 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRROS sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NRCAM Biologics Sequence Review Report 2026: Neuronal cell adhesion molecule Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRCAM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR4A3 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 4 group A member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR4A3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.